Answers are grounded in this paper and cite their sources.
Purpose: Mitotane is an adrenolytic and steroidogenesis-modifying drug with an established role in adrenocortical carcinoma (ACC), but it has also been used in patients with difficult-to-control endogenous Cushing syndrome (CS). Its role outside ACC remains uncertain because the available literature includes historical series, referral-center cohorts, combination rescue regimens, pediatric cases, and case reports with differing treatment goals. This systematic review aimed to define the clinical settings in which mitotane has been used for endogenous CS and to summarize biochemical response, time to control, durability of response, treatment exposure, and toxicity, while distinguishing mitotane-dominant therapy from concurrently initiated combination regimens and oncologic treatment of functioning ACC. Methods: PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from inception through 28 June 2026 using the supplied review dataset. Backward and forward citation searching, reference checking of major reviews, and an eligibility re-audit were updated on 7 August 2026. Reports of patients with biochemically confirmed endogenous CS treated therapeutically with oral mitotane were eligible. Cushing disease (CD), ectopic ACTH syndrome (EAS), other ACTH-dependent or adrenal causes of CS, and cortisol-secreting ACC were considered separately. Non-functioning ACC was excluded from CS-specific efficacy analyses. Complete biochemical control was defined preferentially by normalization of urinary free cortisol (UFC) or by the accepted biochemical criterion used in the individual study. Because of substantial clinical and methodological heterogeneity, study-level findings were emphasized and no overall pooled estimate of efficacy, mortality, or toxicity was calculated. Results: Twenty primary reports were included. Among the largest mitotane-dominant datasets, Luton et al. reported remission in 38 of 46 patients with CD treated with mitotane alone, while Donadille et al. reported UFC normalization in 21 of 23 patients with EAS. In the series by Baudry et al., 48 of 67 long-term treated patients with CD achieved remission, with a median time to remission of 6.7 months. Smaller historical series also reported high response proportions. Schteingart et al. described remission in 29 of 36 patients receiving low-dose mitotane together with pituitary irradiation. In contrast, Kamenicky et al. demonstrated rapid biochemical control in severe ACTH-dependent CS when mitotane, metyrapone, and ketoconazole were initiated simultaneously, making it impossible to attribute the early response specifically to mitotane. A 2024 EAS case series also described sustained cortisol control in three patients with advanced pancreatic neuroendocrine tumors. Reported adverse effects included gastrointestinal, neurological, hepatic, lipid, thyroid, gonadal, and adrenal or mineralocorticoid disturbances. Overall certainty of evidence was very low because the available studies were non-randomized, frequently included co-interventions, used heterogeneous outcome definitions, and were subject to substantial selection bias. Conclusion: Mitotane can achieve substantial and sometimes durable control of hypercortisolism in selected patients with endogenous CS, particularly when prolonged adrenal-directed therapy is required and in patients with functioning ACC. Its relatively slow onset limits its use as sole therapy in acute, life-threatening hypercortisolism. The available evidence supports individualized use in specialist practice rather than reliance on a single pooled estimate of efficacy. Prospective multicenter studies with standardized biochemical endpoints, time-to-control measures, therapeutic drug monitoring, and systematic adverse-event reporting are needed.
No takes yet. Share an insight, caveat, or question.
Jha et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: